|
Patent landscape, scope, and claims: |
Executive summary: US Patent 4,717,720 claims a family of substituted benzonaphthalene (naphthoic acid) derivatives defined by a detailed substitution pattern with a required presence of adamantyl or adamantylthio at specific ring positions, plus a broad set of acceptable substituents (alkyl, alkoxy, hydroxy/acyloxy, silyl ethers, thiocycloaliphatics, and polyols) and pharmaceutically acceptable salts. The patent’s enforceable scope is controlled primarily by the core structural formula (where R2 and R3 must include adamantyl or adamantylthio), then narrowed by dependent claim species that lock specific substituent identities, R groups, and explicit named compounds. The patent also claims a composition using any one claimed compound (or salt) in a vehicle for multiple administration routes and a broad concentration band.
Source note: A complete, accurate “landscape” requires identifying (i) the patent’s assignee, (ii) all related family members, (iii) prosecution history, (iv) which compounds are actually tied to a marketed FDA product and Orange Book listing, and (v) concurrent litigations and examiner guidance. Those inputs are not provided here, so the analysis below focuses strictly on claim scope and legal/technical constraints derivable from the claim text you supplied.
US Patent 4,717,720 claim scope: what benzonaphthalene compounds do claim 1 actually cover?
What is the structural “lock” in claim 1? (R2/R3 adamantyl requirement)
Claim 1 is a Markush-structured claim to compounds of a benzonaphthalene/naphthoic-acid framework “of the formula ##STR11##” with multiple variable positions R1 to R6 and R2 to R5 governed by substituent definitions. The most constraining requirement is:
- “provided that at least one of R2 and R3 is adamantyl or adamantylthio.”
This means the claim covers:
- compounds where R2 = adamantyl or R2 = adamantylthio, or
- compounds where R3 = adamantyl or R3 = adamantylthio, or
- compounds where both positions satisfy the adamantyl/adamantylthio condition.
Practically, this is the key “design-around” and “infringement pivot.” Competitors can avoid literal scope only by ensuring neither R2 nor R3 is adamantyl/adamantylthio under the claim’s definition (including adamantylthio forms).
What positions are variable, and how broad are they?
From your claim text, the variables are constrained as follows:
- R1 represents (i) “##STR12##” (the detailed ring/linker substituent is not fully legible in the text dump, but the claim clearly treats R1 as a structured substituent, not free-form substituents).
- R6 = OR7, where R7 can be:
- hydrogen
- alkyl (1–20 carbons)
- monohydroxyalkyl or polyhydroxyalkyl (length and OH counts are later specialized in dependent claims)
- R2 can be:
- hydrogen
- branched/straight chain alkyl (1–15 carbons)
- alkoxy (1–4 carbons)
- cycloaliphatic radical
- R3 can be:
- hydrogen
- hydroxy
- alkyl (1–4 carbons)
- alkoxy (1–10 carbons)
- cycloaliphatic radical (optionally substituted)
- thiocycloaliphatic radical
- “--O--Si(CH3)2--R8” where R8 is linear or branched lower alkyl
- R4 and R5 each can be independently:
- hydrogen
- lower alkyl
- hydroxy
- lower acyloxy
- Claim 1 also covers salts of the compounds.
What does that mean for literal infringement?
Literal infringement is most likely when a candidate compound is within the same core benzonaphthalene/naphthoic-acid scaffold, has:
- the R1-defined substituent pattern of the formula, and
- a matching alkoxy/hydroxy/acyloxy/silyl ether pattern at positions tied to R3/R4/R5, and
- critically, adamantyl or adamantylthio present at R2 and/or R3.
Because the claim is Markush-like and broadly recites multiple classes at each position, many close analogs will fall within literal scope if they satisfy the adamantyl/adamantylthio requirement.
Which dependent claims narrow the compound scope the most (species vs genus)?
Claims 2–12: what substitution “buckets” are explicitly permitted
-
Claim 2: “alkyl is selected from methyl, ethyl, isopropyl, butyl, tert-butyl.”
This narrows any “alkyl” occurrences that correspond to the claim’s “alkyl” definition at R2/R3 positions where that dependent claim is applicable.
-
Claim 3–4: alkoxy chain-length and identities:
- Claim 3: alkoxy has 1–10 carbons
- Claim 4: alkoxy is methoxy, ethoxy, isopropoxy, hexyloxy, decyloxy
-
Claims 5–6: acyloxy identity and size:
- Claim 5: lower acyloxy 1–4 carbons
- Claim 6: acyloxy is acetyloxy or propionyloxy
-
Claims 7–8: monohydroxyalkyl:
- Claim 7: 2 or 3 carbon atoms
- Claim 8: 2-hydroxyethyl or 2-hydroxypropyl
-
Claims 9–10: polyhydroxyalkyl:
- Claim 9: 3–6 carbons and 2–5 hydroxy groups
- Claim 10: selected from 2,3-dihydroxypropyl, 1,3-dihydroxypropyl, or “a residue of pentaerythritol”
-
Claim 11–12: special cycloaliphatic/thiocycloaliphatic:
- Claim 11: cycloaliphatic radical is 1-methylcyclohexyl or 1-adamantyl
- Claim 12: thiocycloaliphatic radical is 1-adamantylthio
These dependent claims are less about changing the adamantyl/adamantylthio requirement and more about specifying which members within the broader R-group classes are included.
Claim 13: another structural subset using primed variables
Claim 13 is a further species-type claim to compounds of the formula “##STR13##” with constraints:
- R'6 = --OR'7
- R'7 = hydrogen or lower alkyl
- R'2 = hydrogen, alkyl, alkoxy or 1-adamantyl
- R'3 = hydrogen, hydroxy, alkyl, alkoxy or 1-adamantylthio
This claim appears to carve out a more specific set where the adamantyl/adamantylthio options are directly tied to R'2 and R'3 definitions. In infringement practice, a candidate compound that matches claim 13 will often satisfy claim 1 as well, but claim 13 can matter for:
- narrowing invalidity attacks (certain prior art may anticipate one subset but not the broader genus), and
- clarifying what the patentee treats as a core commercial “lead.”
Which claim is the “hit list” for explicit compounds: claim 14
Claim 14 is an explicit list of named species (and includes methyl esters and silylated/hydroxy/decyloxy/methoxy substituted variants). The list includes compounds such as:
- 6-[p-(1-adamantylthio)phenyl]-2-naphthoic acid
- methyl ester of 6-[p-(1-adamantylthio)phenyl]-2-naphthoic acid
- 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid
- the methyl ester variants
- methyl ester of 6-[3-(1-adamantyl)-4-tert.butyldimethylsilyloxyphenyl]-2-naphthoic acid
- methyl ester of 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthoic acid
- 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthoic acid
- 6-[3-(1-adamantyl)-4-decyloxyphenyl]-2-naphthoic acid and methyl esters
- 6-[3-(1-adamantyl)-4-hexyloxyphenyl]-2-naphthoic acid and methyl esters
- multiple additional substituted methyl ester / positional variants, including “4-acetoxy”, “4-hydroxy-1-methyl-2-naphthoic acid,” and related methyl ester forms.
This claim functions as:
- an enforcement anchor (specific species),
- a validity hedge (even if parts of the genus are anticipated, some listed species may remain novel), and
- a claim construction guide (it demonstrates the patentee’s understood scope of what “falls within” R-group combinations in the Markush formula).
A product compound that matches one of the listed species is at the highest risk of direct literal infringement.
How broad is the pharmaceutical composition claim (claims 15–16)?
Claim 15: universal vehicle + route coverage
Claim 15 covers:
- “A pharmaceutical composition” comprising
- a “pharmaceutically acceptable vehicle”
- suitable for enteral, parenteral, topical or ocular administration
- and an “effective amount”
- of “at least one compound of claim 1 or a salt thereof.”
This is broad in two respects:
- active ingredient scope: any claim 1 compound or salt, not limited to claim 14 species.
- dosage form/route: enteral, parenteral, topical, ocular.
Claim 16: concentration band
Claim 16 specifies:
- active principle present in 0.0005 to about 5 weight percent of total composition.
This supports enforcement across multiple formulations, including low-dose topical or ocular preparations, and more concentrated oral/parenteral formats, as long as the concentration is within the stated band.
Infringement angle: if a competitor sells a composition in which the claimed compound is present above the low end and uses a vehicle that qualifies as pharmaceutically acceptable, claim 15/16 can be asserted even when the competitor’s main argument is “compound not covered.” Successful enforcement still depends on showing the active compound is within claim 1.
US Patent 4,717,720 enforceability map: what features drive strength vs design-around?
Most important constraint features
- Adamantyl/adamantylthio at R2 and/or R3 (required condition).
- R6 = OR7 structure with R7 including hydrogen and long-chain alkyl up to C20 and polyol motifs.
- R3 includes a large set including hydroxy, alkyl (1–4), alkoxy (1–10), cycloaliphatic and thiocycloaliphatic radicals, plus silyl ether form via --O--Si(CH3)2–R8.
- R4/R5 independently hydroxyl/acyloxy/lower alkyl/hydrogen.
Likely design-around levers
- Replace adamantyl/adamantylthio at R2 and R3 with non-adamantane analogs (or prevent mapping to those values via structural changes that eliminate adamantyl/adamantylthio at both positions).
- Remove or alter the silyl ether motif if the competitor is trying to avoid the R3 “--O--Si(CH3)2–R8” branch; however, that may not help if other branches still read on the same compound.
- Alter the ester form (e.g., carboxylate form) to avoid matching claim 14 species; note this typically does not avoid claim 1 if the core Markush still reads, but it can matter for claim 14-only positions.
Where scope collapses into smaller pockets
- Claims 2, 4, 6, 8, 10, 11, 12, and 13 narrow to defined substituent choices.
- Claim 14 lists specific species; those are easiest to map for infringement and easiest to anticipate if those exact structures appear in earlier art.
Patent landscape framework for US 4,717,720: what other patents typically matter (and how to read them)
Because only the claim text was provided, the actual “landscape” cannot be populated with case dockets, assignees, examiner citations, or related family numbers. The following is the correct analytical framework to apply once those bibliographic records are pulled:
1) Family members (continuations/divisionals)
- Check whether the assignee filed continuations targeting:
- specific R-group subsets (often the same adamantyl scaffold but different substituent ranges),
- ester/salt strategies,
- formulations by route (topical/ocular vs enteral).
2) Overlapping composition patents
- Because claim 15/16 is broad (vehicle + route + concentration range), other patents may cover:
- specific dosage forms (e.g., ocular solutions, suspensions, gels),
- pH/tonicity buffers,
- sustained-release matrices.
- Those formulation patents can exist without touching claim 1’s compound scope.
3) Method-of-use patents
- For benzonaphthalene/naphthoic-acid derivatives, method-of-use patents typically focus on a therapeutic indication, dosing regimen, and patient population.
- Those patents can coexist even if claim 1 is not implicated by a competitor’s compound design.
4) Generic/biosimilar relevance
- If these compounds are small molecules (not biologics), biosimilar does not apply, but generic entry does.
- Key date questions (for litigation or exclusivity calculations) depend on:
- patent expiration (20 years from earliest non-provisional filing, adjusted for PTA),
- any additional unexpired patents in the same family,
- whether Orange Book listings exist for a marketed product using any claim 1 compound.
5) The litigation trigger
- For small-molecule drugs, Paragraph IV and suit timing depend on whether an ANDA references a listed drug and whether a generic challenges specific Orange Book-listed patents.
- For a claim 1 compound family, infringement is asserted by showing the ANDA product contains an active ingredient that reads within the Markush structure.
Key Takeaways
- US 4,717,720 claim 1 covers a genus of substituted benzonaphthalene/naphthoic-acid derivatives with wide permissible substituents, but with a critical requirement that at least one of R2 and R3 is adamantyl or adamantylthio.
- Dependent claims (2–12) narrow substituents to defined alkyl/alkoxy/acyloxy/polyol and specific cycloaliphatic/thiocycloaliphatic options, without removing the adamantyl/adamantylthio locus as the primary mapping constraint.
- Claim 13 further specifies a subset with primed variables where adamantyl/adamantylthio options are explicitly included in R'2/R'3 definitions.
- Claim 14 is the practical enforcement spine for named species, including adamantylthio and adamantyl substituted phenyl-naphthoic acid cores, along with methyl ester forms and silylated, hydroxy, methoxy, hexyloxy, decyloxy, acetoxy variants.
- Claims 15–16 broaden enforcement to formulations containing at least one claim 1 compound in a pharmaceutically acceptable vehicle for enteral, parenteral, topical, or ocular administration, with 0.0005 to 5 wt% active content.
FAQs
1) What is the single most important structural element to check for infringement of US 4,717,720?
Confirm whether the candidate compound has adamantyl or adamantylthio at R2 and/or R3 as required by claim 1.
2) Do methyl ester forms matter for claim 14 infringement?
Yes for matching the listed species in claim 14, but not determinative for claim 1, which is governed by the Markush formula and salts rather than only the ester identity.
3) Can a formulation infringe claims 15–16 if the active ingredient matches only part of the substitution pattern?
Not if the active ingredient fails the claim 1 structure including the adamantyl/adamantylthio requirement; the composition claims require an active ingredient “of claim 1.”
4) How does the silyl ether option affect claim coverage?
Claim 1 includes a R3 branch that covers a --O--Si(CH3)2–R8 silyl ether structure with lower alkyl R8, so removal of the silyl motif may still leave coverage through other permitted R3 options.
5) Which claim is most useful for straightforward claim mapping in litigation?
Claim 14 because it enumerates explicit species, enabling direct structural matching against accused compounds.
References
No external references were provided or cited in the claim text alone.
More… ↓
⤷ Start Trial
|
